Publication:
Is There an Opportunity to De-Escalate Treatments in Selected Patients with Metastatic Hormone-Sensitive Prostate Cancer?

Simple item page
cris.virtualsource.author-orcid693a84c1-f4d5-4094-a42b-311a5b909f6a
datacite.rightsopen.access
dc.contributor.authorGómez-Aparicio, María Antonia
dc.contributor.authorLópez-Campos, Fernando
dc.contributor.authorBuchser, David
dc.contributor.authorLazo, Antonio
dc.contributor.authorWillisch, Patricia
dc.contributor.authorOcanto, Abrahams
dc.contributor.authorSargos, Paul
dc.contributor.authorShelan, Mohamed
dc.contributor.authorCouñago, Felipe
dc.date.accessioned2024-10-26T18:32:12Z
dc.date.available2024-10-26T18:32:12Z
dc.date.issued2024-06-26
dc.description.abstractThe treatment landscape for metastatic hormone-sensitive prostate cancer continues to evolve, with systemic treatment being the mainstay of current treatment. Prognostic and predictive factors such as tumour volume and disease presentation have been studied to assess responses to different treatments. Intensification and de-escalation strategies arouse great interest, so several trials are being developed to further personalize the therapy in these populations. Is there an optimal sequence and a possible option to de-intensify treatment in selected patients with a favourable profile? This and other goals will be the subject of this review.
dc.description.sponsorshipUniversitätsklinik für Radio-Onkologie
dc.identifier.doi10.48350/198984
dc.identifier.pmid39001393
dc.identifier.publisherDOI10.3390/cancers16132331
dc.identifier.urihttps://boris-portal.unibe.ch/handle/20.500.12422/179130
dc.language.isoen
dc.publisherMDPI AG
dc.relation.ispartofCancers
dc.relation.issn2072-6694
dc.relation.organizationDCD5A442BAD6E17DE0405C82790C4DE2
dc.subjectandrogen receptor signalling inhibitors de-intensification metastatic hormone-sensitive prostate cancer treatment intensification
dc.subject.ddc600 - Technology::610 - Medicine & health
dc.titleIs There an Opportunity to De-Escalate Treatments in Selected Patients with Metastatic Hormone-Sensitive Prostate Cancer?
dc.typearticle
dspace.entity.typePublication
dspace.file.typetext
oaire.citation.issue13
oaire.citation.volume16
oairecerif.author.affiliationUniversitätsklinik für Radio-Onkologie
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.date.licenseChanged2024-07-17 11:25:22
unibe.description.ispublishedpub
unibe.eprints.legacyId198984
unibe.refereedtrue
unibe.subtype.articlereview

Files

Original bundle
Now showing 1 - 1 of 1
Name:
cancers-16-02331.pdf
Size:
301.98 KB
Format:
Adobe Portable Document Format
File Type:
text
License:
https://creativecommons.org/licenses/by/4.0
Content:
published
Download

Collections

Publications